Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke | Lei | Pakistan Journal of Medical Sciences
 
مبل راحتی صندلی مدیریتی صندلی اداری میز اداری وبلاگدهی گن لاغری بازی اندروید تبلیغات کلیکی آموزش زبان انگلیسی پاراگلایدر مارکت اندروید تور آهنگ محسن چاوشی مسیح و آرش پروتز سینه پروتز باسن پروتز لب میز تلویزیون

Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke

Hongyan Lei, Yansen Cui, Mei Zheng, Daiqun Yang, Liquan Wang, Ziran Wang

Abstract


Objective: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).

Methods: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.

Results: The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.

Conclusions: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).

doi: http://dx.doi.org/10.12669/pjms.324.9518

How to cite this:Zheng M, Cui Y, Lei H, Yang D, Wang L, Wang Z. Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke. Pak J Med Sci. 2016;32(4):811-816.   doi: http://dx.doi.org/10.12669/pjms.324.9518

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


kalsob-01_1303_01